Part I: The Failing Commercial Architecture The commercial model that generated decades of reliable profit for large-cap pharmaceutical companies was […]

A deep-dive for pharmaceutical IP teams, R&D leads, and institutional investors on intellectual property architecture, regulatory pathways, exclusivity mechanics, and

Let’s start with a number that should make any pharmaceutical strategist put down their coffee: analysts project that emerging markets

Executive Summary Engaging a contract development and manufacturing organization (CDMO) has gone from tactical cost arbitrage to board-level strategic decision.

The launch price of a new medicine is the most durable, highest-stakes financial decision a pharmaceutical company makes. It is

The premise sounds straightforward enough: a blockbuster biologic loses patent protection, a competitor copies it at lower cost, patients save

Section 1: The Economics Nobody Talks About Generic drugs fill roughly 90% of all U.S. prescriptions while accounting for only

A deep-dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Executive Summary The generic pharmaceutical industry is

Defining a Blockbuster Drug in 2026 — and Why the Definition Is Shifting The pharmaceutical industry has operated with a